Evaluation of the effect of modafinil on the pharmacokinetics of encorafenib and binimetinib in patients with BRAF V600-mutant advanced solid tumors
Cancer Chemotherapy and Pharmacology · 2024
DOI: 10.1007/s00280-024-04676-2 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Cancer Chemotherapy and Pharmacology, 2024. Verfasst von Joseph Piscitelli und 6 weiteren Autor:innen. Beteiligte Einrichtung: Pfizer Inc, 10555 Science Center Dr, San Diego, CA, 92121, USA. joseph.piscitelli@pfizer.com. Hauptthemen laut MEDLINE: Modafinil, Benzimidazoles, Carbamates, Drug Interactions. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pfizer Inc..
Abstract (Originalsprache)
Background
A clinical drug-drug interaction (DDI) study was designed to evaluate the effect of multiple doses of modafinil, a moderate CYP3A4 inducer at a 400 mg QD dose, on the multiple oral dose pharmacokinetics (PK) of encorafenib and its metabolite, LHY746 and binimetinib and its metabolite, AR00426032.
Methods
This study was conducted in patients with BRAF V600-mutant advanced solid tumors. Treatment of 400 mg QD modafinil was given on Day 15 through Day 21. Encorafenib 450 mg QD and binimetinib 45 mg BID were administered starting on Day 1. PK sampling was conducted from 0 to 8 h on Day 14 and Day 21. Exposure parameters were calculated for each patient by noncompartmental analysis and geometric least-squares mean ratio. Corresponding 90% confidence intervals were calculated to estimate the magnitude of effects.
Results
Among 11 PK evaluable patients, encorafenib C max and AUC last were decreased in presence of steady-state modafinil by 20.2% and 23.8%, respectively. LHY746 exposures were not substantially changed in the presence of steady-state modafinil.
Conclusion
The results from this clinical study indicate modafinil 400 mg QD had a weak effect on encorafenib PK. Based on these results, encorafenib can be coadministered with a moderate CYP3A4 inducer without dosing adjustment. Clinical trial registration ClinicalTrials.gov NCT03864042, registered 6 March 2019.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pfizer Inc, 10555 Science Center Dr, San Diego, CA, 92121, USA. joseph.piscitelli@pfizer.com.
- Pfizer Inc, Boulder, CO, USA.
- Pierre Fabre Medicament, Toulouse, France.
- Pfizer Inc, New York, NY, USA.
- Pfizer Inc, Collegeville, PA, USA.
- Pfizer Inc, 10555 Science Center Dr, San Diego, CA, 92121, USA.
Förderung
- Pfizer Inc.
Zitieren
APA
Piscitelli, J., Reddy, M. B., Wollenberg, L., Del Frari, L., Gong, J., Matschke, K., & Williams, J. H. (2024). Evaluation of the effect of modafinil on the pharmacokinetics of encorafenib and binimetinib in patients with BRAF V600-mutant advanced solid tumors. Cancer Chemotherapy and Pharmacology. https://doi.org/10.1007/s00280-024-04676-2
Vancouver
Piscitelli J, Reddy MB, Wollenberg L, Del Frari L, Gong J, Matschke K, et al. Evaluation of the effect of modafinil on the pharmacokinetics of encorafenib and binimetinib in patients with BRAF V600-mutant advanced solid tumors. Cancer Chemotherapy and Pharmacology. 2024. doi:10.1007/s00280-024-04676-2
BibTeX
@article{Piscitelli2024,
author = {Piscitelli, Joseph and Reddy, Micaela B and Wollenberg, Lance and Del Frari, Laurence and Gong, Jason and Matschke, Kyle and Williams, Jason H},
title = {Evaluation of the effect of modafinil on the pharmacokinetics of encorafenib and binimetinib in patients with BRAF V600-mutant advanced solid tumors},
journal = {Cancer Chemotherapy and Pharmacology},
year = {2024},
doi = {10.1007/s00280-024-04676-2}
}
EUVIMED